Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Ahmed Hamed Salem et al.|Journal of Clinical Oncology|2017Cited by 752
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|The Lancet Oncology|2017Cited by 378
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Asher Chanan‐Khan et al.|Blood|2017Cited by 271